Creating Broad Access to Our HIV/AIDS Medicines
We expanded our commitment to product affordability and announced Kaletra's price at $1,000 per patient per year in more than 40 low and low-middle income developing countries.
- The new tablet formulation of Kaletra (known as Aluvia in developing countries) was filed or has been approved in 154 developed and developing countries. This represents countries where 95 percent of the world's HIV-positive population lives.
Since 2001, Abbott has made our HIV medicines widely available in all of
Africa and the 69 Least Developed Countries, as designated by the United
Nations, at a no-profit price of $500 per patient per year. We expanded our
commitment to product affordability and announced Kaletra's price at $1,000 per
patient per year in more than 40 low and low-middle income developing
countries, a price that is significantly discounted from prices in
industrialized countries.
Today, Kaletra is the most broadly registered second-line HIV medicine
worldwide and is among the lowest-priced second-line HIV medicines, branded or
generic, in the developing world. In 2006, the World Health Organization
guidelines stated that lopinavir/ritonavir (Kaletra) tablets are the preferred
protease inhibitor in resource-restricted societies. Abbott's program is
designed to ensure long-term sustainable access to high-quality HIV medicines
and includes:
- Sustainable pricing for governments, nongovernmental organizations and public funders of HIV medicines in developing countries;
- Broad registration of the new, nonrefrigerated tablet formulation throughout the world, including Africa, Asia, Latin America and the Caribbean;
- Investment in additional manufacturing capacity to meet demand for high-quality second-line HIV treatments; and development of a pediatric low-dose tablet formulation to meet the treatment needs of HIV-positive children globally.
Worldwide, nearly 40 million people are living with HIV/AIDS. We created our program to help address the great need to scale up treatment in the developing world. The process involved consultations with governments, global health experts, regulators, medical professionals and patient organizations.
We also held briefings with HIV patient advocates from the United States, Europe and developing countries, and discussed our global HIV strategy and long-term approach to sustainability. We listened to their concerns and feedback. We will continue to engage our stakeholders and provide updates on our progress.
Meeting the challenge of HIV/AIDS requires contributions from many stakeholders, as well as approaches that align business interests with those of patients around the world.
Read more about our HIV/AIDS efforts at HIV and Abbott.
We report regularly on our efforts in our Annual Report and Global Citizenship Report.
